These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 578254)

  • 1. Combination chemotherapy with doxorubicin and lomustine. Treatment of refractory Hodgkin's disease.
    Williams SD; Einhorn LH
    JAMA; 1977 Oct; 238(15):1659-61. PubMed ID: 578254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP.
    Diggs CH; Wiernik PH; Sutherland JC
    Cancer; 1981 Jan; 47(2):224-8. PubMed ID: 6161689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin.
    Levi JA; Wiernik PH; Diggs CH
    Med Pediatr Oncol; 1977; 3(1):33-40. PubMed ID: 65727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].
    Osieka R; Bruntsch U; Gallmeier WM; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1976 Aug; 101(32):1177-82. PubMed ID: 59661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy for non-Hodgkin's lymphoma.
    Ng PR; Todd D; Khoo RK
    Cancer Treat Rep; 1982 Nov; 66(11):1977-9. PubMed ID: 7139640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease.
    Diggs CH; Wiernik PH; Levi JA; Kvols LK
    Cancer; 1977 May; 39(5):1949-54. PubMed ID: 870162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.
    Kurnick JE; White M; Ware DE; Robinson WA
    Cancer Chemother Rep; 1975; 59(6):1147-50. PubMed ID: 56989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
    Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
    Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new combination chemotherapy for resistant Hodgkin disease.
    Vinciguerra V; Coleman M; Jarowski CI; Degnan TJ; Silver RT
    JAMA; 1977 Jan; 237(1):33-5. PubMed ID: 62854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ Long-term evaluation of the effect of a chemotherapy protocol using vincristine, adriamycin, procarbazine and prednisone (VAPP) on advanced Hodgkin's disease].
    Marinone G; Colle R; Mombelloni P
    Minerva Med; 1978 Apr; 69(18):1255-61. PubMed ID: 662153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.